<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01759732</url>
  </required_header>
  <id_info>
    <org_study_id>AMCPHO-SCT1202</org_study_id>
    <nct_id>NCT01759732</nct_id>
  </id_info>
  <brief_title>Haploidentical Stem Cell Transplantation for Children With Acquired Severe Aplastic Anemia</brief_title>
  <official_title>Haploidentical Stem Cell Transplantation With Fixed Dose of T Cells After in Vitro T Cell Depletion Using CD3 Monoclonal Antibody for Children With Acquired Severe Aplastic Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <brief_summary>
    <textblock>
      Rationale: Fludarabine, cyclophosphamide, anti-thymocyte globulin and low-dose total body
      irradiation (LD-TBI) may induce the engraftment cross the immunologic barrier in the setting
      of HLA-haploidentical allogeneic hematopoietic cell transplantation. In addition, depletion
      of CD3 cells may contribute to prevent developing severe acute graft versus host disease
      (GVHD) in haploidentical transplantation.

      Purpose: Phase II trials to evaluate the efficacy of haploidentical stem cell transplantation
      with fixed dose of T cells after in vitro T cell depletion using CD3 monoclonal antibody for
      children with acquired severe aplastic anemia
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess engraftment rate and survival of haploidentical stem cell transplantation with fixed dose of T cells after in vitro T cell depletion using CD3 monoclonal antibody for children with acquired severe aplastic anemia</measure>
    <time_frame>2 years posttransplant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess engraftment and graft failure</measure>
    <time_frame>28 days posttransplant</time_frame>
    <description>Number of patients who failed to engraft by 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate the risk of acute GVHD</measure>
    <time_frame>100 days posttransplant</time_frame>
    <description>Number of patients with acute GVHD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess treatment related mortality</measure>
    <time_frame>100 days posttransplant</time_frame>
    <description>Number of death after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate overall survival and failure free survival</measure>
    <time_frame>1 year posttransplant</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Acquired Aplastic Anemia</condition>
  <arm_group>
    <arm_group_label>HAPLO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>40mg/M2 once daily IV on days -7 to -4</description>
    <arm_group_label>HAPLO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>60 mg/kg IV on day-3 and -2</description>
    <arm_group_label>HAPLO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
    <arm_group_label>HAPLO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <arm_group_label>HAPLO</arm_group_label>
    <other_name>Beginning on day 4 and continuing until blood counts recover</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total body irradiation</intervention_name>
    <description>200 cGy per day on D-5 &amp; -4</description>
    <arm_group_label>HAPLO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CD3-depleted hematopoietic cell transplantation</intervention_name>
    <description>Immunogenetic depletion on CliniMACS</description>
    <arm_group_label>HAPLO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of life-threatening marrow failure (severe aplastic anemia) of nonmalignant
             etiology meeting 2 of the following criteria:

               -  Granulocyte count &lt; 500/mm3,

               -  Corrected reticulocyte count &lt; 1%,

               -  Platelet count &lt; 20,000/mm3

          -  No HLA-identical family member or closely matched (8 of 8 HLA-locus match) unrelated
             marrow donor available

          -  HLA-haploidentical related donor available

        Exclusion Criteria:

          -  Paroxysmal nocturnal hemoglobinuria or Fanconi anemia

          -  Clonal cytogenetic abnormalities or myelodysplastic syndromes

          -  Active fungal infections

          -  HIV positive

          -  Severe disease other than aplastic anemia that would severely limit the probability of
             survival during the graft procedure

          -  Pregnant or nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ho Joon Im, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ho Joon Im, MD, PhD</last_name>
    <phone>82-2-3010-3371</phone>
    <email>hojim@amc.seoul.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ho Joon Im, MD, PhD</last_name>
      <phone>82-2-3010-3371</phone>
      <email>hojim@amc.seoul.kr</email>
    </contact>
    <investigator>
      <last_name>Kyung Nam Koh, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/anemia.html</url>
    <description>Anemia</description>
  </link>
  <reference>
    <citation>Burroughs LM, Woolfrey AE, Storer BE, Deeg HJ, Flowers ME, Martin PJ, Carpenter PA, Doney K, Appelbaum FR, Sanders JE, Storb R. Success of allogeneic marrow transplantation for children with severe aplastic anaemia. Br J Haematol. 2012 Jul;158(1):120-8. doi: 10.1111/j.1365-2141.2012.09130.x. Epub 2012 Apr 26.</citation>
    <PMID>22533862</PMID>
  </reference>
  <reference>
    <citation>Tolar J, Deeg HJ, Arai S, Horwitz M, Antin JH, McCarty JM, Adams RH, Ewell M, Leifer ES, Gersten ID, Carter SL, Horowitz MM, Nakamura R, Pulsipher MA, Difronzo NL, Confer DL, Eapen M, Anderlini P. Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels. Biol Blood Marrow Transplant. 2012 Jul;18(7):1007-11. doi: 10.1016/j.bbmt.2012.04.014. Epub 2012 Apr 27.</citation>
    <PMID>22546497</PMID>
  </reference>
  <reference>
    <citation>Xu LP, Liu KY, Liu DH, Han W, Chen H, Chen YH, Zhang XH, Wang Y, Wang FR, Wang JZ, Huang XJ. A novel protocol for haploidentical hematopoietic SCT without in vitro T-cell depletion in the treatment of severe acquired aplastic anemia. Bone Marrow Transplant. 2012 Dec;47(12):1507-12. doi: 10.1038/bmt.2012.79. Epub 2012 May 28.</citation>
    <PMID>22635243</PMID>
  </reference>
  <results_reference>
    <citation>Koh KN, Im HJ, Kim BE, Choi ES, Jang S, Kwon SW, Park CJ, Seo JJ. Haploidentical haematopoietic stem cell transplantation using CD3 or CD3/CD19 depletion and conditioning with fludarabine, cyclophosphamide and antithymocyte globulin for acquired severe aplastic anaemia. Br J Haematol. 2012 Apr;157(1):139-42. doi: 10.1111/j.1365-2141.2011.08924.x. Epub 2011 Nov 5.</citation>
    <PMID>22055111</PMID>
  </results_reference>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 30, 2012</study_first_submitted>
  <study_first_submitted_qc>December 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 3, 2013</study_first_posted>
  <last_update_submitted>December 30, 2012</last_update_submitted>
  <last_update_submitted_qc>December 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 3, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Ho Joon Im</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Aplastic anemia</keyword>
  <keyword>T cell dose</keyword>
  <keyword>CD3 depletion</keyword>
  <keyword>Haploidentical hematopoietic stem cell transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

